Disc Medicine (formerly known as Gemini Therapeutics) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of treatments for patients suffering from hematologic diseases. It offers a portfolio of clinical and preclinical product candidates for the treatment of erythropoietic porphyrias, anemia of myelofibrosis, anemia of chronic kidney disease, polycythemia vera, and other hematologic disorders.